The Tumor microenvironment(TME) refers to the environment around which cancer cells proliferate, including blood vessels, immune cells, fibroblasts, signal molecules and extracellular matrix ECM), adipocyte, etc.
Immune cell in TME are composed of cytotoxic CD8 T cells, CD4 Th1 cells, natural killer cells, as well as immunosuppressive cells (Treg), myeloid-derived suppressor cells (MDSC), and tumor-related macrophages (TAM). In addition, oxygen concentration, nutrients (glucose, amino acids, fatty acids, etc.), metabolites, and pH in TME are also known to affect cancer progression. In general, TME is well known to have immunosuppressed and metabolic stress, which acts as a major obstacle to chemotherapy.
Therefore, in order to develop effective chemotherapy, it is essential to understand and overcome the high heterogeneity and complexity within TME, and to enhance anticancer immunity by regulating dynamic networks within TME.
We, AGATHONBIO, is under-developing a next-generation immuno-oncology drug that modulate this tumor immune microenvironment.
The cause of autoimmune diseases is not yet clear, but it is presumed to be caused by complex causes such as heredity, diet, hormones, stress, and representative diseases include rheumatoid arthritis, Behcet’s disease, Crohn’s, ankylosing spondylitis, type 1 diabetes, malignant anemia, multiple sclerosis, and myasthenia gravis.
All of these autoimmune diseases have different symptoms because our body's immune system attacks our body, although steroids and immunosuppressants, and inhibitor of apoptosis are used as common treatments, these drugs do not have disease-modifying effects, are highly likely to recur, and there are concerns about serious side effects when taken for a long time.
Therefore, the autoimmune disease market is a field with high unmet medical needs, requiring innovative new drugs.